金十数据5月12日讯，在美国总统特朗普表示他将签署一项降低处方药和药品价格的行政命令后，欧洲 制药公司的股票周一早盘下跌。在法兰克福上市的诺和诺德、阿斯利康、葛兰素史克和罗氏控股的股价 下跌1%至5%不等，表现逊于大盘。此前亚洲制药股也出现下跌。在日本，制药板块下跌超过4%，成为 东京证券交易所33个行业分类指数中表现最差的板块。印度制药股也走低。 欧洲制药股跟随亚洲同行下跌 ...

5月8日，总投资达20.4亿元的罗氏制药中国全新生物制药生产基地投资项目启动，同一天，阿斯利康无 锡小分子药物新工厂正式开工，总投资达4.75亿美元（约合34.41亿元）。近年来，包括拜耳、赛诺菲、 诺和诺德在内的多家跨国医药巨头也在用真金白银加码布局中国市场。除了巨大的市场规模，日益崛起 的中国创新药，也正被多家海外医药巨头"争抢"。 多家跨国药企先后加码布局中国市场 罗氏制药中国全新生物制药生产基地投资项目用地约53亩，建筑面积约2.5万平方米，将用于罗视佳 （法瑞西单抗注射液）的本地化生产，该药为全球首个获批的眼科双特异性抗体药物，目前已被纳入国 家医保。新项目建成后，将成为罗氏制药在中国的第二个创新药物生产基地，此次加码投资，旨在通过 加强罗氏在中国的供应链和本地化生产布局，全面强化端到端的完整医药价值产业链。 无独有偶，阿斯利康无锡小分子药物新工厂也在同一天正式开工。新工厂总投资达4.75亿美元，占地约 3万平方米，将装备两套前沿的片剂连续制造工艺设备和七条可持续药品包装生产线，主要生产阿斯利 康在研管线中的心血管创新药，预计2028年第四季度投产。新工厂建成后，将进一步提升无锡生产供应 基地的产能 ...

新项目位于上海浦东新区张江高科技园区，用地约53亩，建筑面积约2.5万平方米，将用于罗视佳® （法瑞西单抗注射液）的本地化生产。这是全球首个获批的眼科双特异性抗体药物，目前已被纳入国家 医保，为眼底病患者提供创新的治疗方案。该项目预计将于2029年正式落成，2031年正式投产。 罗氏制药中国总裁边欣表示，罗氏对中国市场的承诺不变，此次加码布局全新的生产基地，是罗氏在华 发展历程中的一个重要里程碑。它标志着罗氏在华本地化生产能力取得了长足发展，更代表着罗氏在中 国这一重要市场实现了更多创新药本地化生产的重大突破。这一突破性尝试使罗氏能够更加贴近中国患 者、更快响应本土需求。 5月8日，罗氏制药中国宣布投资20.4亿元人民币，在上海新建生物制药生产基地，以加强罗氏在中国的 供应链和本地化生产布局，全面强化端到端的完整医药价值产业链。 边欣表示，面向未来，罗氏将进一步探索更多创新药本地化生产的落地，积极助力中国生物医药产业的 可持续发展，在加速引入全球创新产品的同时，罗氏将持续推动深化合作、加码在华布局，惠及更多中 国患者，助力"健康中国2030"目标早日实现。 这一全新生物制药生产基地建成后，将成为罗氏制药在中国 ...

罗氏宣布投资超20亿人民币 在沪新建生物制药生产基地 智通财经5月8日电，罗氏制药中国5月8日宣布投资20.4亿元人民币，用于在上海新建生物制药生产基 地。当天投资项目启动仪式举行。企业表示，此次加码投资旨在通过强化企业在华供应链和本地化生产 布局，全面强化端到端的完整医药价值产业链。项目位于张江高科技园区，用地约53亩，建筑面积约 2.5万平方米。项目预计2029年正式落成，2031年正式投产。基地将用于罗视佳®（法瑞西单抗注射 液）的本地化生产 ，不断满足中国患者对于创新疗法需求。 (解放日报) ...

5月7日，罗氏制药中国宣布，创新双特异性抗体高罗华 (英文商品名：Columvi ，中英文通用名：格菲 妥单抗/Glofitamab)新适应症已获得中国国家药品监督管理局的上市批准，联合吉西他滨与奥沙利铂 (GemOx)用于治疗不适合自体造血干细胞移植(ASCT)的复发或难治性弥漫大B细胞淋巴瘤非特指型 (DLBCL NOS)成人患者(2L+DLBCL)。 ...

A view of the sign and logo of the Roche Holding AG headquarters on April 11, 2025 in Basel, Switzerland. Sedat Suna | Getty Images News | Getty ImagesCOPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss candidate.The deal, announced in March and set to close in the second quarter, marks the Swiss pharma's latest bid to compete with weight loss heavyweights Novo Nordis ...

Company Overview - Roche Holding AG (RHHBY) currently holds a Momentum Style Score of B, indicating a favorable position in momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [4] Price Performance - Over the past week, RHHBY shares increased by 1.59%, while the Zacks Large Cap Pharmaceuticals industry rose by 3.52% [6] - In a longer time frame, RHHBY's monthly price change is 3.56%, outperforming the industry's 1.85% [6] - Over the last quarter, RHHBY shares have increased by 0.59%, and over the past year, they have gained 37.04% [7] - In comparison, the S&P 500 has moved -7.43% over the last quarter and 12.15% over the past year [7] Trading Volume - RHHBY's average 20-day trading volume is 2,416,640 shares, which serves as a price-to-volume baseline for assessing momentum [8] Earnings Outlook - In the past two months, two earnings estimates for RHHBY have moved higher, with no downward revisions, boosting the consensus estimate from $2.83 to $2.93 [10] - For the next fiscal year, three estimates have increased, with no downward revisions during the same period [10] Conclusion - Considering the positive price performance, trading volume, and favorable earnings outlook, RHHBY is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [12]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Roche Holding AG (RHHBY) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Roche Holding AG is one of 1000 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different g ...

Basel, 30 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an update to the European Union (EU) label for Phesgo®, a subcutaneous (SC) fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. If approved, administration of Phesgo outside of a clinical setting (such ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...